Matches in Wikidata for { <http://www.wikidata.org/entity/Q64217541> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- Q64217541 description "assaig clínic" @default.
- Q64217541 description "clinical trial" @default.
- Q64217541 description "clinical trial" @default.
- Q64217541 description "clinical trial" @default.
- Q64217541 description "clinical trial" @default.
- Q64217541 description "ensaio clínico" @default.
- Q64217541 description "ensayo clínico" @default.
- Q64217541 description "ensayu clínicu" @default.
- Q64217541 description "essai clinique" @default.
- Q64217541 description "klinisch onderzoek" @default.
- Q64217541 description "клінічне випробування" @default.
- Q64217541 name "A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis" @default.
- Q64217541 type Item @default.
- Q64217541 label "A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis" @default.
- Q64217541 prefLabel "A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis" @default.
- Q64217541 P1050 Q64217541-C0C7ABBC-9A00-4A98-971E-D280C3E1087F @default.
- Q64217541 P1132 Q64217541-3A77BCED-E468-46EE-9B8D-0F97E85D0CA4 @default.
- Q64217541 P1476 Q64217541-F13D0B7F-A06B-4715-93E6-CF1938E5D289 @default.
- Q64217541 P17 Q64217541-0118067E-9A3E-4758-88AA-129284D0D592 @default.
- Q64217541 P17 Q64217541-084E22C4-323E-4EEE-B749-5A0A34B7930F @default.
- Q64217541 P17 Q64217541-1136777B-2A09-4336-9D3E-A6E0C8EF9800 @default.
- Q64217541 P17 Q64217541-73265F52-C0A6-4B4A-83AB-367232C98FD0 @default.
- Q64217541 P17 Q64217541-7B204882-80C8-4542-BF57-1329C3869294 @default.
- Q64217541 P17 Q64217541-7EA1E7EA-ED72-4307-9DF8-C438ABD407B1 @default.
- Q64217541 P17 Q64217541-839EAA13-A1E8-4AB4-8234-95BA54DF7121 @default.
- Q64217541 P17 Q64217541-A1D0BCD8-4AC2-4136-900A-903EA88DC6AF @default.
- Q64217541 P17 Q64217541-C33543D4-6D4E-4A4F-A4ED-EF9687643742 @default.
- Q64217541 P17 Q64217541-C46B9AC4-897F-41AE-B275-61C1F8C57ACB @default.
- Q64217541 P1813 Q64217541-E8EDAD04-E565-48E5-B78E-E628452892FF @default.
- Q64217541 P2899 Q64217541-93CFBBC7-FDDA-4897-89C2-6842E964B181 @default.
- Q64217541 P3098 Q64217541-80DF859A-CCD7-4B2B-ADBB-35DE98B15C06 @default.
- Q64217541 P31 Q64217541-EB6D54C1-4955-4F3D-B3AB-7E00E782A967 @default.
- Q64217541 P580 Q64217541-1A8C449A-510F-48FF-A5D8-CBD3AB079D32 @default.
- Q64217541 P582 Q64217541-4A342BDB-821A-4ECA-A534-9F689DC7DFEE @default.
- Q64217541 P6099 Q64217541-0E4C45C8-125E-4CEB-ACF9-5AB5A2995965 @default.
- Q64217541 P8363 Q64217541-BCFF26A4-C24B-4713-984E-FC804949CDCA @default.
- Q64217541 P1050 Q170990 @default.
- Q64217541 P1132 "+570" @default.
- Q64217541 P1476 "A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis" @default.
- Q64217541 P17 Q145 @default.
- Q64217541 P17 Q191 @default.
- Q64217541 P17 Q212 @default.
- Q64217541 P17 Q214 @default.
- Q64217541 P17 Q219 @default.
- Q64217541 P17 Q258 @default.
- Q64217541 P17 Q29 @default.
- Q64217541 P17 Q30 @default.
- Q64217541 P17 Q36 @default.
- Q64217541 P17 Q96 @default.
- Q64217541 P1813 "SPIRIT P3" @default.
- Q64217541 P2899 "+18" @default.
- Q64217541 P3098 "NCT02584855" @default.
- Q64217541 P31 Q30612 @default.
- Q64217541 P580 "2015-09-14T00:00:00Z" @default.
- Q64217541 P582 "2018-10-30T00:00:00Z" @default.
- Q64217541 P6099 Q42824827 @default.
- Q64217541 P8363 Q78089383 @default.